[CAS NO. 41621-49-2] Ciclopiroxolamine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [41621-49-2]

Catalog

HY-B0450A

Brand

MCE

CAS

41621-49-2

DESCRIPTION [41621-49-2]

Overview

MDL	MFCD00078997
Molecular Weight	268.35
Molecular Formula	C14H24N2O3
SMILES	O=C1C=C(C)C=C(C2CCCCC2)N1O.NCCO

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

Summary

Ciclopirox olamine (Ciclopirox ethanolamine) is a synthetic antifungal agent that can be used for superficial mycoses reseaech. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes , yeasts , molds , and many Gram-positive and Gram-negative species pathogenic ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05482763	University of Rome Tor Vergata	Onychomycosis\|Resistant Infection\|Nail Diseases	July 20, 2022
NCT00382330	University of Medicine and Dentistry of New Jersey\|Rutgers, The State University of New Jersey	Vulvar Cancer		Not Applicable
NCT00127868	Chen, Catherine, M.D.\|Williams, Judith V., M.D.\|Hubbard, Thomas W., M.D.\|Eastern Virginia Medical School	Tinea Capitis	March 2005	Not Applicable
NCT01419847	Rady Children´s Hospital, San Diego	Onychomycosis	March 2002	Phase 4
NCT02866032	Moberg Pharma AB	Distal Subungual Onychomycosis	September 2016	Phase 3
NCT01646580	Ferrer Internacional S.A.	Dermatomycoses	October 2008	Phase 4
NCT02679911	Galderma R&D	Foot Dermatoses	September 2015	Phase 4
NCT00990587	University Health Network, Toronto\|The Leukemia and Lymphoma Society	Hematologic Malignancy\|Acute Lymphocytic Leukemia\|Chronic Lymphocytic Leukemia\|Myelodysplasia\|Acute Myeloid Leukemia\|Chronic Myelogenous Leukemia\|Hodgkin´s Disease	October 2009	Phase 1
NCT02961634	MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA\|Buranello e Rodrigues Consultoria em Desenvolvimento Farmacêutico Ltda ME	Onychomycosis	April 2017	Phase 3
NCT01139749	Federal University of São Paulo	Seborrhea\|Seborrheic Dermatitis\|Quality of Life	October 2011	Phase 4
NCT00804193	Padagis LLC	Tinea Pedis	June 2004	Not Applicable
NCT00802672	Padagis LLC	Tinea Pedis	December 2003	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL ( 93.16 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7265 mL	18.6324 mL	37.2648 mL
5 mM	0.7453 mL	3.7265 mL	7.4530 mL
10 mM	0.3726 mL	1.8632 mL	3.7265 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (7.75 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (7.75 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: 2.08 mg/mL (7.75 mM); Clear solution; Need warming

* All of the co-solvents are available by MCE.

References

[1] Niewerth M, et al. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother. 2003 Jun;47(6):1805-17.

Synonyms

2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, compd. with 2-aminoethanol (1:1)

Ethanol, 2-amino-, compd. with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (1:1)

HOE 296

1-Hydroxy-4-methyl-6-cyclohexyl-2-pyridinone ethanolamine salt

Ciclopirox olamine

Batrafen

Loprox

Mycoster

Brumixol

Micoxolamina

Terit

Ciclochem

NSC 336278

Ciclopirox ethanolamine (1:1)

Sebiprox

Fungowas

Selergo